HWM
SMMT icon

Hohimer Wealth Management’s Summit Therapeutics SMMT Stock Holding History

Hohimer Wealth Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.94M Buy
+339,100
New +$6.01M 0.49% 49

Other funds holding SMMT

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
WMP
Wealth Management Partners Tucson, Arizona $425M AUM 60.71% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Hohimer Wealth Management's SMMT Position: Q2 2026 in Review

Hohimer Wealth Management opened a new position in Summit Therapeutics (SMMT) in Q2 2026: 339,100 shares worth $4.94M. The stake represents 0.49% of the portfolio and ranks #49 among its holdings.

47 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Hohimer Wealth Management held 339,100 shares of Summit Therapeutics worth $4.94M as of Q2 2026.
  • Summit Therapeutics was a new Hohimer Wealth Management position in Q2 2026.
  • Summit Therapeutics made up 0.49% of Hohimer Wealth Management's portfolio in Q2 2026, its #49 holding.
  • 47 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Hohimer Wealth Management's 13F filing for Q2 2026, filed 3 Aug 2026.